LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)       0.79  -0.05 (-5.95%)

0.79  -0.05 (-5.95%)

US5393192027 - Common Stock - After market: 0.7505 -0.04 (-5%)

News Image
a month ago - Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF...

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday!

News Image
2 months ago - InvestorPlace

CRWD Stock Alert: What to Know About CrowdStrike’s New President

CrowdStrike (CRWD) stock is in the news Wednesday as the cybersecurity company announced Michael Sentonas as its new president.

News Image
2 months ago - InvestorPlace

Tripadvisor (TRIP) Stock Receives Double Upgrade From Bank of America

Tripadvisor (TRIP) stock is getting a boost on Wednesday after the company got a double upgrade and new price target from Bank of America.

News Image
2 months ago - InvestorPlace

BABA Stock Alert: Alibaba Tests AI Tool to Compete With ChatGPT

Alibaba (BABA) stock is on the move Wednesday as investors react to news of the company testing an AI tool to rival ChatGPT.

News Image
2 months ago - InvestorPlace

Why Is Lixte Biotech (LIXT) Stock Down 29% Today?

Lixte Biotech (LIXT) stock is dropping on Wednesday but it's not due to any negative news from the drug discovery company.

News Image
2 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday!

News Image
2 months ago - Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE...

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

News Image
6 months ago - Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...